Lipocine (NASDAQ:LPCN – Get Free Report) announced its quarterly earnings data on Thursday. The specialty pharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.31, Zacks reports. Lipocine had a negative return on equity of 64.75% and a negative net margin of 755.39%. The company had revenue of $2.29 million for the quarter, compared to the consensus estimate of $0.16 million.
Lipocine Price Performance
Shares of NASDAQ:LPCN traded up $0.04 during trading on Friday, reaching $1.57. 507,960 shares of the stock were exchanged, compared to its average volume of 5,694,962. Lipocine has a 1-year low of $1.36 and a 1-year high of $12.37. The stock has a fifty day moving average of $1.92 and a two-hundred day moving average of $3.77. The firm has a market cap of $12.94 million, a price-to-earnings ratio of -1.23 and a beta of 0.49.
Insider Activity
In other Lipocine news, Director John Higuchi purchased 15,970 shares of the firm’s stock in a transaction on Wednesday, September 30th. The stock was acquired at an average price of $2.23 per share, for a total transaction of $35,613.10. Following the purchase, the director owned 241,365 shares of the company’s stock, valued at $538,243.95. This trade represents a 7.09% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders acquired 37,568 shares of company stock valued at $82,174. 4.69% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on the company. HC Wainwright reaffirmed a “neutral” rating and set a $4.00 target price on shares of Lipocine in a research note on Monday, September 21st. Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a research note on Saturday, July 18th. Weiss Ratings upgraded Lipocine from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, October 29th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Lipocine in a research report on Tuesday, September 22nd. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $4.00.
Read Our Latest Analysis on LPCN
Lipocine Company Profile
Lipocine Inc is a biopharmaceutical company focused on developing oral therapies for conditions with significant unmet medical needs. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and clinical performance of active pharmaceutical ingredients that may otherwise have limited effectiveness when taken orally.
Lipocine’s lead product is Tlando, an oral testosterone replacement therapy containing testosterone undecanoate. The U.S. Food and Drug Administration approved Tlando in 2022 for testosterone replacement therapy in adult males with hypogonadism associated with an underlying medical condition.
Read More
- Five stocks we like better than Lipocine
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
